DexCom Inc. ($DXCM) Stock Forecast: Down 1.8% Today

What is DexCom Inc.?

Dexcom Inc. (DXCM) is a company specializing in continuous glucose monitoring technology, with a focus on expanding its market to include individuals with Type 2 diabetes and prediabetes. The stock experienced a significant decrease in value today.

Why is DexCom Inc. going down?

DXCM stock is down 1.8% on Feb 3, 2026 16:17

• The decline in DXCM stock value could be linked to investors selling off their shares to secure profits following a period of substantial growth and optimistic forecasts for 2026.
• The recent change in leadership, marked by the appointment of new CEO, Jake Leach, may have prompted some uncertainty among investors, leading to selling pressure.
• Despite Peterson Wealth Services increasing their ownership in DXCM, the mixed activity among company insiders and the general market sentiment may have influenced the downward trend.
• The upcoming earnings reports from Diodes (DIOD) and Universal Technical Institute (UTI) are potential factors impacting investor confidence in the healthcare sector, contributing to the negative pressure on DXCM stock.

DXCM Price Chart

DXCM Technical Analysis

DXCM News

New Dexcom CEO Takes on ‘Thrilling’ Task Leading CGM Giant

Jake Leach has taken over as CEO and President of Dexcom, succeeding Kevin Sayer. Leach, who joined Dexcom in 2004, is focused on expanding the company's continuous glucose monitoring (CGM) technology to a broader patient base, including those with Type 2 diabetes and prediabetes, after the company saw record growth in 2025 and projects over $5 billion in revenue for 2026. He emphasizes the “thrilling” opportunity to guide the organization into the future and further grow its global impact in metabolic health.

https://www.sdbj.com/life-sciences/medical-devices/new-dexcom-ceo-takes-on-thrilling-task-leading-cgm-giant/

Diodes (DIOD) Projected to Post Quarterly Earnings on Tuesday

Diodes (NASDAQ:DIOD) is expected to report its Q4 2025 earnings before market open on Tuesday, February 10th, with analysts forecasting earnings of $0.26 per share. The company previously reported $0.37 EPS in Q3 2025 on revenues of $392.17 million. Analysts project $2.00 EPS for the current fiscal year and $3.00 for the next, while the stock currently holds an average "Hold" rating and an average target price of $55.33.

https://www.marketbeat.com/instant-alerts/diodes-diod-projected-to-post-quarterly-earnings-on-tuesday-2026-02-03/

Peterson Wealth Services Grows Stock Position in DexCom, Inc. $DXCM

Peterson Wealth Services significantly increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 423.6% in the third quarter, holding 28,937 shares worth approximately $1.95 million. Insider activity was mixed, with a director selling shares while the COO acquired a substantial amount. Wall Street analysts maintain a "Moderate Buy" consensus with a price target of $85.00, against the current trading price around $72.53.

https://www.marketbeat.com/instant-alerts/filing-peterson-wealth-services-grows-stock-position-in-dexcom-inc-dxcm-2026-02-03/

Jones Financial Companies Lllp Buys 61,627 Shares of Abbott Laboratories $ABT

Jones Financial Companies Lllp increased its stake in Abbott Laboratories by 14.9% in Q3, purchasing over 61,000 additional shares and bringing its total holdings to 475,202 shares valued at approximately $63.51 million. Abbott Laboratories recently reported its quarterly earnings, meeting EPS estimates but falling short on revenue, and subsequently raised its quarterly dividend to $0.63. Analyst sentiment for ABT is moderately positive, with a consensus "Moderate Buy" rating and an average price target of $137.05, despite some recent price target trims.

https://www.marketbeat.com/instant-alerts/filing-jones-financial-companies-lllp-buys-61627-shares-of-abbott-laboratories-abt-2026-02-03/

Universal Technical Institute (UTI) Reports Q4: Everything You Need To Know Ahead Of Earnings

Universal Technical Institute (UTI) is set to report its Q4 earnings on Wednesday after market close. Analysts anticipate an 8% year-on-year revenue growth to $217.5 million, a slowdown from the previous year's 15.3% increase. The company has a history of consistently beating revenue estimates and enters earnings with an average analyst price target significantly above its current share price.

https://finviz.com/news/296544/universal-technical-institute-uti-reports-q4-everything-you-need-to-know-ahead-of-earnings

Trending Today

Cigna Corporation ($CI) Stock Forecast: Up 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 3.6% Today

Capital One Financial Corporation ($COF) Stock Forecast: Down 4.5% Today

Goldman Sachs Group Inc. (The) ($GS) Stock Forecast: Down 4.5% Today

Eli Lilly and Company ($LLY) Stock Forecast: Down 5.2% Today

Roku Inc. ($ROKU) Stock Forecast: Down 8.5% Today

Alcoa Corporation ($AA) Stock Forecast: Down 7.5% Today

Huntington Ingalls Industries Inc. ($HII) Stock Forecast: Down 9.0% Today

HP Inc. ($HPQ) Stock Forecast: Down 5.3% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 7.4% Today

DexCom Inc. Price History

03.01.2026 - DXCM Stock was down 1.8%

• The decline in DXCM stock value could be linked to investors selling off their shares to secure profits following a period of substantial growth and optimistic forecasts for 2026.
• The recent change in leadership, marked by the appointment of new CEO, Jake Leach, may have prompted some uncertainty among investors, leading to selling pressure.
• Despite Peterson Wealth Services increasing their ownership in DXCM, the mixed activity among company insiders and the general market sentiment may have influenced the downward trend.
• The upcoming earnings reports from Diodes (DIOD) and Universal Technical Institute (UTI) are potential factors impacting investor confidence in the healthcare sector, contributing to the negative pressure on DXCM stock.

05.00.2026 - DXCM Stock was up 2.8%

• The bullish movement in DXCM stock today can be attributed to the company's position at an inflection point in the competitive glucose-monitoring market, with positive sentiment from analysts on its future prospects.
• Recent insider transactions, including some purchases at lower prices, suggest continued long-term confidence in DXCM despite short-term valuation concerns, contributing to the positive momentum.
• The company's innovative products and favorable regulatory environment are likely driving investor optimism and contributing to the stock's strong performance in today's trading session.

10.11.2025 - DXCM Stock was up 4.1%

• The rise in DXCM's stock price could be linked to investors potentially seeing recent class action lawsuits and allegations as temporary hurdles that DexCom can navigate.
• Despite legal concerns regarding unauthorized design alterations to its devices and resulting reliability and health issues, investors may have confidence in DexCom's ability to tackle these challenges and uphold its market position.
• Investor faith in DXCM may also be bolstered by positive updates or announcements regarding the company's product pipeline, partnerships, or financial performance, overshadowing the short-term legal uncertainties.
• Overall, today's bullish movement in DXCM's stock suggests that investors are concentrating on the company's long-term growth potential and resilience in the face of legal obstacles, rather than solely dwelling on the ongoing lawsuits and allegations.

11.10.2025 - DXCM Stock was up 5.7%

• The rise in DXCM's stock value may stem from investors perceiving the recent securities fraud class action lawsuits as temporary obstacles that DexCom will likely surmount.
• Despite the legal hurdles, investor confidence in DexCom's capacity to innovate within the healthcare technology industry could be bolstering the stock's performance.
• Growing interest in the stock might also be a result of speculation surrounding potential resolutions or settlements related to the securities law violations, fostering a positive outlook among traders.

12.00.2026 - DXCM Stock was up 5.3%

• DexCom's stock had a notable bullish trend, propelled by robust preliminary Q4 results that surpassed revenue expectations and demonstrated significant growth in both domestic and international markets.
• The introduction of DexCom's G7 15-Day sensor and the FDA approval for Smart Basal technology have been key factors in fostering positive market sentiment, revealing a high demand for the company's advanced products.
• Analysts at Morgan Stanley maintained an Overweight rating for DexCom, pointing to the strong Q4 results and the appointment of a new CEO as favorable catalysts for the company's future growth.
• While there are varied analyst opinions on DexCom's valuation, the general market sentiment remains optimistic, with investors looking forward to the company's sustained revenue growth, enhanced margins, and expansion strategies for 2026.

11.10.2025 - DXCM Stock was up 5.1%

• Today's bullish movement in DXCM's stock may be linked to the favorable market response to its robust Q3 growth and expanded CGM coverage, positioning the company for ongoing adoption despite growing competition.
• Despite facing legal challenges such as securities fraud class action lawsuits and allegations of securities law violations, investors appear to be more focused on the company's growth potential and momentum driven by innovation.
• While some investors have taken a bearish stance in the options market, this sentiment does not seem to have significantly impacted DXCM's stock performance today, as the overall optimistic outlook on the company's future prospects overshadowed these issues.

12.00.2026 - DXCM Stock was up 5.1%

• Dexcom experienced a strong bullish movement recently due to several positive factors:
• The fourth-quarter revenue surpassed expectations, mainly due to the successful launch of the G7 15-Day sensor, showcasing the company's innovation and responsiveness to market needs.
• The appointment of a new President and CEO, Jake Leach, coupled with plans to introduce an AI-enabled Stelo app, reflects a strategic shift towards advanced technology in diabetes management.
• Analysts have expressed optimistic views on Dexcom's performance for 2026, projecting revenue growth and improved margins, which has boosted investor confidence and generated a bullish sentiment.
• Despite concerns raised by some analysts about weaker gross margins and potential pricing pressures, Dexcom's proactive approach to product development and leadership changes has outweighed these worries, leading to an increase in the stock price.

13.10.2025 - DXCM Stock was up 5.1%

• An upcoming lead plaintiff deadline in a securities lawsuit may have initially caused volatility in the stock.
• Despite bearish opinions in the options market, positive news surrounding DXCM's strong growth in Q3 and focus on innovation likely reassured investors and supported the bullish movement.
• Ongoing securities fraud class action lawsuits and legal reminders could have led to short-term fluctuations. However, the overall positive view on DXCM's performance and market position has been more prominent, driving the bullish trend.
• Investors appear to be placing more emphasis on the company's growth potential and competitive standing rather than its legal challenges, leading to an increase in the stock price.

06.00.2026 - DXCM Stock was up 5.1%

• The bullish movement in DXCM stock today can be attributed to the unveiling of a new app feature by a competitor aimed at enhancing mealtime decisions for individuals with diabetes. This innovation in the diabetes management space may have positively influenced investor sentiment towards DexCom.
• The market may also be reacting to the detailed overview of DexCom's stock performance and financial data, showcasing its fundamental strength and role in continuous glucose monitoring systems.
• Additionally, the nuanced view on Dexcom's valuation and long-term growth prospects from top institutional shareholders and recent insider trades might have instilled confidence in investors, contributing to the bullish momentum.

22.00.2026 - DXCM Stock was up 4.4%

• Despite challenges like a recent Class 1 recall for some G7 receivers, Dexcom announced an impressive Q3 2024 revenue growth of 22% year-over-year, amounting to $1.2 billion. This growth was fueled by expanding its customer base and launching new products such as the Stelo for non-insulin users.
• Analysts have a positive consensus on DXCM, rating it as a "Strong Buy" with an average price target of $85.00, indicating a potential upside of 22.6%. This positive sentiment stems from the company's strong performance in the healthcare industry and its ability to capture the growing market of diabetes patients embracing CGM technology.
• The rise in DXCM's stock price today is attributed to its strong financial performance, favorable analyst ratings, and the overall growth opportunities in the healthcare sector, particularly in patient monitoring.
• Institutional ownership of DXCM remains high at 97.75%, despite Fisher Funds Management LTD selling a portion of its stake, showcasing ongoing confidence in the company's future prospects and market position.

07.10.2025 - DXCM Stock was down 5.1%

• The decrease in DXCM stock value might be linked to legal actions taken against the company alleging securities fraud, which has caused uncertainty among investors.
• Despite reporting strong double-digit growth in Q3 earnings and increasing its projected revenue for 2025, the stock price dropped, potentially indicating that the legal issues have overshadowed the positive financial performance.
• Investor sentiment towards DXCM appears pessimistic, possibly driven by worries concerning the lawsuits' impact on the company's image and long-term growth prospects.

31.09.2025 - DXCM Stock was down 14.3%

• Despite strong growth in Q3 and an increase in revenue projections for 2025, DXCM saw a decline in its stock price, signaling a disconnect between its performance and investor expectations.
• An ongoing examination into potential breaches of fiduciary duties by certain company officials could have contributed to investor unease and the stock's bearish performance.
• Legal actions initiated by a law firm on behalf of DXCM investors within a specific timeframe might have added to the negative market sentiment surrounding the company.
• Even surpassing Q3 earnings and revenue forecasts may not have been enough to counterbalance overarching market apprehensions and legal uncertainties, resulting in the decline in the stock's value.